[go: up one dir, main page]

CN1793159A - Process for synthesizing cholester-3 bata, 5 alpha, 6 bata, 19-tetrahydroxy-24-one and derivative - Google Patents

Process for synthesizing cholester-3 bata, 5 alpha, 6 bata, 19-tetrahydroxy-24-one and derivative Download PDF

Info

Publication number
CN1793159A
CN1793159A CN 200510121374 CN200510121374A CN1793159A CN 1793159 A CN1793159 A CN 1793159A CN 200510121374 CN200510121374 CN 200510121374 CN 200510121374 A CN200510121374 A CN 200510121374A CN 1793159 A CN1793159 A CN 1793159A
Authority
CN
China
Prior art keywords
add
solution
courage steroid
ketone
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200510121374
Other languages
Chinese (zh)
Other versions
CN100436474C (en
Inventor
颜光美
张静夏
丘鹏新
黄亦俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Cellprotek Pharmaceutical Co Ltd
Original Assignee
Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Yat Sen University filed Critical Sun Yat Sen University
Priority to CNB200510121374XA priority Critical patent/CN100436474C/en
Publication of CN1793159A publication Critical patent/CN1793159A/en
Priority to AU2006332419A priority patent/AU2006332419A1/en
Priority to PCT/CN2006/001627 priority patent/WO2007076655A1/en
Application granted granted Critical
Publication of CN100436474C publication Critical patent/CN100436474C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)

Abstract

本发明公开了一种胆甾-3β,5α,6β,19-四羟基-24-酮及衍生物的合成方法,该方法以猪去氧胆酸为原料,制备3β-乙酰氧基-胆甾-5-烯-24-酸,通过和氯化亚砜反应制备成胆甾酰氯,超声波辐射下和异丙基镉试剂反应得3β-乙酰氧基-胆甾-5-烯-24-酮,再与N-溴代丁二酰亚胺/高氯酸水溶液体系反应得到3β-乙酰氧基-胆甾-5α-溴-6β-羟基-24-酮,之后用二乙酰氧基碘代苯生成3β-乙酰氧基-胆甾-5α-溴-6β,19-环氧-24-酮,用锌粉/冰醋酸体系还原生成3β,19-二乙酰氧基-胆甾-5-烯-24-酮;再用氧化剂氧化5,6位双键,水解反应得胆甾-3β,5α,6β,19-四羟基-24-酮;最后和甲基三苯基溴化膦反应合成24-亚甲基-胆甾-3β,5α,6β,19-四醇;和肼反应合成胆甾-3β,5α,6β,19-四羟基-24-双腙。本发明的合成方法具有原料廉价易得、合成路线科学合理、各步合成产率高等特点,目标化合物对低钾诱导的神经元调亡细胞有显著的保护作用。The invention discloses a method for synthesizing cholesteryl-3β, 5α, 6β, 19-tetrahydroxy-24-one and its derivatives. The method uses hyodeoxycholic acid as a raw material to prepare 3β-acetyloxy-cholesteryl- 5-ene-24-acid, prepared by reacting with thionyl chloride into cholesteryl chloride, reacting with isopropyl cadmium reagent under ultrasonic radiation to obtain 3β-acetoxy-cholest-5-en-24-one, and then React with N-bromosuccinimide/perchloric acid aqueous system to obtain 3β-acetoxy-cholesta-5α-bromo-6β-hydroxy-24-one, and then use diacetoxyiodobenzene to generate 3β -Acetoxy-cholesta-5α-bromo-6β,19-epoxy-24-one, reduced by zinc powder/glacial acetic acid system to generate 3β,19-diacetoxy-cholesta-5-ene-24- Ketone; then oxidize the 5 and 6 double bonds with an oxidizing agent, and hydrolyze to obtain cholesteryl-3β, 5α, 6β, 19-tetrahydroxy-24-ketone; finally react with methyl triphenylphosphine bromide to synthesize 24-methylene Cholesta-3β, 5α, 6β, 19-tetraol; react with hydrazine to synthesize cholesta-3β, 5α, 6β, 19-tetrahydroxy-24-dihydrazone. The synthesis method of the invention has the characteristics of cheap and easy-to-obtain raw materials, scientific and reasonable synthesis route, high synthesis yield of each step, etc., and the target compound has significant protective effect on neuron apoptosis cells induced by low potassium.

Description

胆甾-3β,5α,6β,19-四羟基-24-酮及衍生物的合成方法Synthetic method of cholestan-3β, 5α, 6β, 19-tetrahydroxy-24-one and its derivatives

技术领域technical field

本发明涉及胆甾-3β,5α,6β,19-四羟基-24-酮(结构如I)及衍生物的合成方法。The invention relates to a synthesis method of cholesta-3β, 5α, 6β, 19-tetrahydroxyl-24-one (structure such as I) and derivatives.

背景技术Background technique

24-亚甲基-胆甾-3β,5α,6β,19-四醇(结构如式II)是从南海软珊瑚Nephthea albida及N.tiexieralv erseveldt中分离得到的一种多羟基甾体化合物(王贵阳,李凤英,曾陇梅等,高等学校化学学报,1992,13,623-627)。该化合物对人体直肠癌细胞、人体肺癌细胞、鼠类淋巴癌细胞均具有较强的杀伤能力(Chang-Yih Duh,Shang-Kwei,Mei-Jen Chu et al.,J.Nat.Prod.,1998,61,1022-1024),对多种炎症有显著的抗炎作用(王正濂,许实波,刘清等,热带海洋,1999,18,27-32),该化合物对低钾诱导的神经元凋亡细胞有显著的保护作用。24-methylene-cholesta-3β, 5α, 6β, 19-tetraol (structure such as formula II) is a polyhydroxy steroid compound (Wang Guiyang, Li Fengying, Zeng Longmei, etc., Chemical Journal of Chinese Universities, 1992, 13, 623-627). The compound has strong killing ability to human rectal cancer cells, human lung cancer cells and mouse lymphoma cells (Chang-Yih Duh, Shang-Kwei, Mei-Jen Chu et al., J.Nat.Prod., 1998 , 61, 1022-1024), has significant anti-inflammatory effects on a variety of inflammations (Wang Zhenglian, Xu Shibo, Liu Qing et al., Tropical Ocean, 1999, 18, 27-32), the compound can inhibit the neuronal apoptosis induced by low potassium Cells have a significant protective effect.

该化合物在海洋生物中的含量极低,直接用海洋生物原料提取目前尚存在很多问题,研究合成该化合物具有很高的药用价值。合成该化合物的中间体胆甾-3β,5α,6β,19-四羟基-24-酮及含氮衍生物对低钾诱导的神经元凋亡细胞有显著的保护作用。The content of this compound in marine organisms is extremely low, and there are still many problems in the direct extraction of marine biological raw materials. The research and synthesis of this compound has high medicinal value. The intermediate cholestan-3β, 5α, 6β, 19-tetrahydroxyl-24-one and nitrogen-containing derivatives of the synthetic compound have significant protective effects on neuronal apoptosis cells induced by low potassium.

发明内容Contents of the invention

本发明的目的是提供一种胆甾-3β,5α,6β,19-四羟基-24-酮及衍生物的合成方法。The object of the present invention is to provide a synthetic method of cholestan-3β, 5α, 6β, 19-tetrahydroxy-24-one and its derivatives.

本发明的合成方法以猪去氧胆酸为原料,制备3β-乙酰氧基-胆甾-5-烯-24-酸通过和氯化亚砜反应制备成胆甾酰氯,超声波辐射下和异丙基镉试剂反应得3β-乙酰氧基-胆甾-5-烯-24-酮,再与N-溴代丁二酰亚胺/高氯酸水溶液体系中反应得到3β-乙酰氧基-胆甾-5α-溴-6β-羟基-24-酮,二乙酰氧基碘代苯氧化关环生成3β-乙酰氧基-胆甾-5α-溴-6,19-环氧-24-酮,接着用锌粉/冰醋酸体系或锌粉/醇体系还原生成3β,19-二乙酰氧基-胆甾-5-烯-24-酮,再通过碱解得胆甾-5-烯-3β,19-羟基-24-酮;用氧化剂氧化、水解反应得胆甾-3β,5α,6β,19-四羟基-24-酮;和甲基三苯基溴化膦反应合成24-亚甲基-胆甾-3β,5α,6β,19-四醇;和肼反应合成胆甾-3β,5α,6β,19-四羟基-24-双腙。反应路线如下图所示:The synthetic method of the present invention uses hyodeoxycholic acid as a raw material to prepare 3β-acetoxy-cholest-5-ene-24-acid by reacting with thionyl chloride to prepare cholesteryl chloride, and reacting with isopropyl under ultrasonic radiation The cadmium reagent is reacted to obtain 3β-acetoxy-cholest-5-en-24-one, and then reacted with N-bromosuccinimide/perchloric acid aqueous solution to obtain 3β-acetoxy-cholest-5- 5α-bromo-6β-hydroxy-24-one, oxidative ring closure of diacetoxyiodobenzene to 3β-acetoxy-cholesta-5α-bromo-6,19-epoxy-24-one, followed by zinc powder/glacial acetic acid system or zinc powder/alcohol system to generate 3β, 19-diacetoxy-cholest-5-en-24-one, and then get cholest-5-ene-3β, 19-hydroxyl by alkaline hydrolysis -24-ketone; Oxidation and hydrolysis with oxidant to obtain cholestan-3β, 5α, 6β, 19-tetrahydroxy-24-ketone; reaction with methyl triphenylphosphine bromide to synthesize 24-methylene-cholesteryl- 3β, 5α, 6β, 19-tetraol; react with hydrazine to synthesize cholesta-3β, 5α, 6β, 19-tetrahydroxy-24-dihydrazone. The reaction scheme is shown in the figure below:

I.胆甾-3β,5α,6β,19-四羟基-24-酮;I. Cholesta-3β, 5α, 6β, 19-tetrahydroxy-24-one;

II.24-亚甲基-胆甾-3β,5α,6β,19-四醇;II. 24-methylene-cholesta-3β, 5α, 6β, 19-tetrol;

III.胆甾-3β,5α,6β,19-四羟基-24-双腙;III. Cholesta-3β, 5α, 6β, 19-tetrahydroxy-24-dihydrazone;

IV.3β-乙酰氧基-胆甾-5-烯-24-酸;IV.3β-Acetoxy-cholest-5-en-24-oic acid;

V.3β-乙酰氧基-胆甾-5-烯-24-酮;V.3β-Acetoxy-cholest-5-en-24-one;

VI.3β-乙酰氧基-胆甾-5α-溴-6β-羟基-24-酮;VI.3β-Acetoxy-cholesta-5α-bromo-6β-hydroxy-24-one;

VII.3β-乙酰氧基-胆甾-5α-溴-6β,19-环氧-24-酮;VII.3β-Acetoxy-cholesta-5α-bromo-6β,19-epoxy-24-one;

VIII.3β,19-二乙酰氧基-胆甾-5-烯-24-酮;VIII.3β,19-diacetoxy-cholest-5-en-24-one;

IXa.3β,19-二乙酰氧基-胆甾-5,6β-环氧-24-酮;IXa. 3β,19-diacetoxy-cholesta-5,6β-epoxy-24-one;

IXb.3β,19-二乙酰氧基-胆甾-5,6α-环氧-24-酮;IXb.3β,19-diacetoxy-cholesta-5,6α-epoxy-24-one;

X.3β,19-二乙酰氧基-胆甾-5,6-二羟基-24-酮。X. 3β,19-Diacetoxy-cholesta-5,6-dihydroxy-24-one.

本发明的合成方法的具体步骤是:The concrete steps of synthetic method of the present invention are:

(1)IV参照文献(Bharucha KR,Buckley GC,Cross CK,et al.Can J Chem.,1955,34:982-990.)合成;(1) IV was synthesized with reference to literature (Bharucha KR, Buckley GC, Cross CK, et al. Can J Chem., 1955, 34:982-990.);

(2)将IV溶于无水苯加入氯化亚砜,加入催化量的吡啶,在室温下搅拌2~4小时,减压浓缩至干,再补加苯继续浓缩,带出残留的氯化亚砜,得黄色粘稠的液体;(2) Dissolve IV in anhydrous benzene, add thionyl chloride, add a catalytic amount of pyridine, stir at room temperature for 2 to 4 hours, concentrate under reduced pressure to dryness, add benzene to continue concentration, and bring out residual chloride Sulfoxide, yellow viscous liquid;

(3)称取干燥镁粉,加入无水乙醚,滴加异溴丙烷/无水乙醚溶液,加完后超声辐射15~30分钟,冷却后分批加入氯化镉,在25~40℃下在超声波辐射下搅拌,冰浴冷却下,将上步产物的30~40%无水苯溶液慢慢滴加到反应体系中,滴完后继续超声波辐射回流1~2小时,冰浴冷却后,滴加1∶1盐酸水溶液,用苯萃取,苯层用蒸馏水洗至中性,干燥,减压浓缩,硅胶柱层析,得白色固体V;(3) Weigh dry magnesium powder, add anhydrous diethyl ether, dropwise add isobromopropane/anhydrous diethyl ether solution, irradiate with ultrasound for 15-30 minutes after adding, add cadmium chloride in batches after cooling, at 25-40°C Stir under ultrasonic radiation, under ice bath cooling, slowly add 30-40% anhydrous benzene solution of the product in the previous step into the reaction system dropwise, continue ultrasonic radiation and reflux for 1-2 hours after dropping, after ice bath cooling, 1:1 hydrochloric acid aqueous solution was added dropwise, extracted with benzene, the benzene layer was washed with distilled water until neutral, dried, concentrated under reduced pressure, and subjected to silica gel column chromatography to obtain white solid V;

(4)取白色固体V,加入有机溶剂溶解,再加入HClO4及水,然后在避光条件下分批加入N-丁二酰亚胺,控制温度低于10℃,之后在15~20℃下反应1~2小时,向反应液中加入10%Na2S2O8水溶液,分层后,上层浓缩,下层用CH2Cl2萃取,合并有机层,用饱和NaHCO3溶液洗涤,再用蒸馏水洗涤至中性,干燥,减压浓缩,硅胶柱层析,得白色固体VI;(4) Take the white solid V, add organic solvent to dissolve, then add HClO 4 and water, then add N-succinimide in batches under the condition of avoiding light, control the temperature below 10°C, and then add it at 15-20°C The reaction was carried out for 1 to 2 hours, and 10% Na 2 S 2 O 8 aqueous solution was added to the reaction liquid. After the layers were separated, the upper layer was concentrated, and the lower layer was extracted with CH 2 Cl 2 . The organic layers were combined, washed with saturated NaHCO 3 solution, and then washed with Wash with distilled water until neutral, dry, concentrate under reduced pressure, and perform silica gel column chromatography to obtain white solid VI;

(5)取化合物VI,溶入环己烷/苯混合液,加入氧化剂,20~40℃搅拌下,紫外灯照射7~8小时,反应液依次用10%硫代硫酸钠水溶液,饱和NaHCO3溶液及蒸馏水洗涤至中性,干燥,减压浓缩得浅黄色化合物VII;(5) Take compound VI, dissolve it into cyclohexane/benzene mixture, add an oxidizing agent, under stirring at 20-40°C, irradiate with ultraviolet light for 7-8 hours, and then use 10% sodium thiosulfate aqueous solution, saturated NaHCO 3 The solution and distilled water were washed to neutrality, dried, and concentrated under reduced pressure to obtain light yellow compound VII;

(6)取化合物VIII加入冰醋酸溶解,加入锌粉,搅拌回流20~24小时;趁热抽滤,滤液用二氯甲烷萃取,萃取液分别用饱和碳酸氢钠溶液及蒸馏水洗至中性,干燥,减压浓缩,硅胶柱层析,得浅黄色粘稠液体VIII;(6) Take compound VIII and add glacial acetic acid to dissolve, add zinc powder, stir and reflux for 20 to 24 hours; suction filter while hot, extract the filtrate with dichloromethane, and wash the extract with saturated sodium bicarbonate solution and distilled water until neutral, Dry, concentrate under reduced pressure, and perform silica gel column chromatography to obtain light yellow viscous liquid VIII;

(7)取化合物VIII加入二氯甲烷溶解,加入氧化剂,室温下搅拌,减压除去二氯甲烷,渣块用乙酸乙酯溶解,然后加10%亚硫酸钠溶液洗涤至无色,水洗至中性,干燥,减压浓缩,得白色固体IXa,将其加入丙酮溶解,加入高氯酸,室温下搅拌,调pH至中性,减压蒸去丙酮,用二氯甲烷萃取,干燥,减压浓缩,得白色固体X;(7) Take compound VIII and add dichloromethane to dissolve it, add an oxidizing agent, stir at room temperature, remove the dichloromethane under reduced pressure, dissolve the slag with ethyl acetate, then add 10% sodium sulfite solution to wash until colorless, and wash with water until neutral, Dry and concentrate under reduced pressure to obtain a white solid IXa, add acetone to dissolve it, add perchloric acid, stir at room temperature, adjust pH to neutral, evaporate acetone under reduced pressure, extract with dichloromethane, dry, and concentrate under reduced pressure, A white solid X was obtained;

(8)取化合物VIII加入88%甲酸溶解,沸水浴加热5分钟,冷却至室温,加入氧化剂,室温放置24小时,用水稀释后,用乙酸乙酯萃取,然后加10%亚硫酸钠溶液洗涤至无色,水洗至中性,干燥,减压浓缩,得白色固体IXb;(8) Dissolve compound VIII by adding 88% formic acid, heat in a boiling water bath for 5 minutes, cool to room temperature, add an oxidizing agent, place at room temperature for 24 hours, dilute with water, extract with ethyl acetate, then add 10% sodium sulfite solution to wash until colorless , washed with water to neutrality, dried, and concentrated under reduced pressure to obtain white solid IXb;

(9)将上步产物IXb或X溶解在甲醇中,加入浓度为3%的氢氧化钾醇溶液,加热回流15~30分钟,调pH为中性,减压蒸馏除去甲醇,乙酸乙酯萃取,有机层干燥,减压蒸去溶剂,得浅黄色固体,硅胶柱层析,得白色固体I;(9) Dissolve the product IXb or X of the previous step in methanol, add potassium hydroxide alcohol solution with a concentration of 3%, heat and reflux for 15 to 30 minutes, adjust the pH to neutral, remove methanol by distillation under reduced pressure, and extract with ethyl acetate , the organic layer was dried, and the solvent was evaporated under reduced pressure to give a light yellow solid, and silica gel column chromatography gave a white solid I;

(10)将甲基三苯基溴化膦加入无水四氢呋喃溶液中,注入正丁基锂,注入量以甲基三苯基溴化膦刚好溶解为宜,室温下搅拌反应4~6小时,将上步中的I加入反应体系,继续反应2~3小时,将反应液迅速倒入饱和的氯化铵溶液中,用乙醚萃取,醚层干燥,减压蒸去溶剂,得浅黄色固体,硅胶柱层析,得白色固体II;(10) Add methyl triphenyl phosphine bromide into anhydrous tetrahydrofuran solution, inject n-butyllithium, the injected amount should be just dissolved in methyl triphenyl phosphine bromide, stir and react at room temperature for 4 to 6 hours, Add I in the previous step to the reaction system, continue to react for 2 to 3 hours, quickly pour the reaction solution into a saturated ammonium chloride solution, extract with ether, dry the ether layer, evaporate the solvent under reduced pressure, and obtain a light yellow solid. Silica gel column chromatography gave white solid II;

(11)将I加入乙醇溶解,加入肼的水溶液中,解热回流,减压蒸去溶剂,加入水,调pH为中性,乙酸乙酯萃取,得白色固体,硅胶柱层析,得白色固体III。(11) Dissolve I in ethanol, add it to the aqueous solution of hydrazine, defrost and reflux, evaporate the solvent under reduced pressure, add water, adjust the pH to neutral, extract with ethyl acetate to obtain a white solid, and conduct silica gel column chromatography to obtain a white solid. Solid III.

上述反应步骤中,步骤(2)中II的苯溶液的浓度是25~45%,氯化亚砜的量是II的摩尔数的1.0~2.0倍;步骤(3)中镁粉的量是II的摩尔数的1.2~3.0倍;步骤(4)中的有机溶剂为四氢呋喃或二氧六环;步骤(5)中的氧化剂为二乙酰氧基碘代苯或四醋酸铅;步骤(7)中的氧化剂为高锰酸钾/硫酸铜或间氯过苯甲酸;步骤(8)中的氧化剂为30%双氧水。In the above-mentioned reaction steps, the concentration of the benzene solution of II in the step (2) is 25~45%, and the amount of sulfur oxychloride is 1.0~2.0 times of the molar number of II; In the step (3), the amount of magnesium powder is II 1.2~3.0 times of the number of moles; The organic solvent in the step (4) is tetrahydrofuran or dioxane; The oxidizing agent in the step (5) is diacetoxy iodobenzene or lead tetraacetate; The The oxidizing agent is potassium permanganate/copper sulfate or m-chloroperbenzoic acid; the oxidizing agent in the step (8) is 30% hydrogen peroxide.

本发明的合成方法的反应路线科学合理、合成物的产率高,合成的中间体胆甾-3β,5α,6β,19-四羟基-24-酮,24-亚甲基-胆甾-3β,5α,6β,19-四醇;及胆甾-3β,5α,6β,19-四羟基-24-双腙对低钾诱导的神经元调亡细胞具有显著的保护作用。The reaction route of the synthesis method of the present invention is scientific and reasonable, the yield of the compound is high, and the synthesized intermediates cholesta-3β, 5α, 6β, 19-tetrahydroxyl-24-ketone, 24-methylene-cholesta-3β , 5α, 6β, 19-tetrol; and cholesterin-3β, 5α, 6β, 19-tetrahydroxy-24-dihydrazone have significant protective effects on low potassium-induced neuronal apoptosis.

具体实施方式Detailed ways

以下实施例用以说明本发明,但本发明的保护范围并不仅限以下实施例。除非有特别说明,以下实施例中:I代表胆甾-3β,5α,6β,19-四羟基-24-酮;II代表24-亚甲基-胆甾-3β,5α,6β,19-四醇;III代表胆甾-3β,5α,6β,19-四羟基-24-双腙;IV代表3β-乙酰氧基-胆甾-5-烯-24-酸;V代表3β-乙酰氧基-胆甾-5-烯-24-酮;VI代表3β-乙酰氧基-胆甾-5α-溴-6β-羟基-24-酮;VII代表3β-乙酰氧基-胆甾-5α-溴-6β,19-环氧-24-酮;VIII代表3β,19-二乙酰氧基-胆甾-5-烯-24-酮;IXa代表3β,19-二乙酰氧基-胆甾-5,6β-环氧-24-酮;IXb代表3β,19-二乙酰氧基-胆甾-5,6α-环氧-24-酮;X代表3β,19-二乙酰氧基-胆甾-5,6-二羟基-24-酮。The following examples are used to illustrate the present invention, but the protection scope of the present invention is not limited to the following examples. Unless otherwise specified, in the following examples: I represents cholesta-3β, 5α, 6β, 19-tetrahydroxy-24-one; II represents 24-methylene-cholesta-3β, 5α, 6β, 19-tetra Alcohol; III stands for cholest-3β, 5α, 6β, 19-tetrahydroxy-24-dihydrazone; IV stands for 3β-acetoxy-cholest-5-en-24-acid; V stands for 3β-acetoxy- Cholesta-5-en-24-one; VI represents 3β-acetoxy-cholesta-5α-bromo-6β-hydroxy-24-one; VII represents 3β-acetoxy-cholesta-5α-bromo-6β , 19-epoxy-24-one; VIII represents 3β, 19-diacetoxy-cholest-5-ene-24-one; IXa represents 3β, 19-diacetoxy-cholesta-5,6β- Epoxy-24-one; IXb represents 3β, 19-diacetoxy-cholesta-5,6α-epoxy-24-one; X represents 3β, 19-diacetoxy-cholesta-5,6- Dihydroxy-24-one.

实施例1Example 1

胆甾-3β,5α,6β,19-四羟基-24-酮的合成Synthesis of Cholesta-3β, 5α, 6β, 19-tetrahydroxy-24-one

(1)取化合物(V)100克,加入300ml苯,20ml氯化亚砜,1ml吡啶,在室温下搅拌2小时,减压浓缩至干,除去残留的氯化亚砜,得酰氯化合物用200ml苯溶解,备用。取20克干燥的镁粉,加入60ml无水乙醚,在60%超声波辐射下滴注73ml异溴丙烷的无水乙醚溶液,加完继续超声15~30分钟,冷却后分四批加入78克氯化镉,在25~40℃下开60%超声波振荡半小时。冰水冷却下,慢慢滴加酰氯的苯溶液,滴毕继续超声回流2小时。加冰水冷冻30分钟后,滴加150ml(1∶1)盐酸水溶液,用苯萃取三次,苯层用蒸馏水洗至中性,无水硫酸钠干燥,减压浓缩,硅胶柱层析,得白色固体(VI)。(1) Take 100 grams of compound (V), add 300 ml of benzene, 20 ml of thionyl chloride, and 1 ml of pyridine, stir at room temperature for 2 hours, concentrate under reduced pressure to dryness, remove residual thionyl chloride, and obtain 200 ml of acid chloride compound. Dissolve benzene and set aside. Take 20 grams of dry magnesium powder, add 60ml of anhydrous ether, drip 73ml of isobromopropane anhydrous ether solution under 60% ultrasonic radiation, continue ultrasonication for 15-30 minutes after adding, add 78 grams of chlorine in four batches after cooling Cadmium chloride, 60% ultrasonic vibration at 25-40°C for half an hour. Under ice-water cooling, the benzene solution of acid chloride was slowly added dropwise, and ultrasonic reflux was continued for 2 hours after the drop. After freezing with ice water for 30 minutes, add 150ml (1:1) hydrochloric acid aqueous solution dropwise, extract three times with benzene, wash the benzene layer with distilled water until neutral, dry over anhydrous sodium sulfate, concentrate under reduced pressure, and perform silica gel column chromatography to obtain white Solid (VI).

(2)取白色固体(VI)20克,加入20mL四氢呋喃溶解,加入适量HClO4及水,然后在避光条件下降20克N-丁二酰亚胺分批加入到反应液中,控制温度低于10℃,之后在15~20℃下反应2小时。向反应液中加入10%Na2S2O8水溶液,分层后,用CH2Cl2萃取,合并有机层,用饱和NaHCO3溶液洗涤,再用蒸馏水洗涤至中性,无水硫酸钠干燥,减压浓缩,硅胶柱层析,得白色固体(VII)。(2) Take 20 grams of white solid (VI), add 20 mL of tetrahydrofuran to dissolve, add appropriate amount of HClO 4 and water, then add 20 grams of N-succinimide to the reaction solution in batches under dark conditions, and control the temperature. At 10°C, then react at 15-20°C for 2 hours. Add 10% Na 2 S 2 O 8 aqueous solution to the reaction solution, separate the layers, extract with CH 2 Cl 2 , combine the organic layers, wash with saturated NaHCO 3 solution, and then wash with distilled water until neutral, dry over anhydrous sodium sulfate , concentrated under reduced pressure, and subjected to silica gel column chromatography to obtain a white solid (VII).

(3)取化合物(VII)5克,溶入1000mL环己烷/苯混合液,加入4克二乙酰氧基碘代苯,2.8克碘,搅拌下,40℃下紫外灯照射2小时,反应液依次用10%硫代硫酸钠水溶液,饱和NaHCO3溶液及蒸馏水洗涤至中性,无水硫酸钠干燥,减压浓缩得浅黄色粘稠状化合物(VIII)。(3) Take 5 grams of compound (VII), dissolve it into 1000 mL of cyclohexane/benzene mixed solution, add 4 grams of diacetoxyiodobenzene, 2.8 grams of iodine, stir, and irradiate with ultraviolet light at 40 ° C for 2 hours to react The solution was successively washed with 10% aqueous sodium thiosulfate solution, saturated NaHCO 3 solution and distilled water until neutral, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain light yellow viscous compound (VIII).

(4)取化2克合物(VIII)加入40冰醋酸溶解,加入6锌粉,搅拌回流20~24小时。趁热抽滤,滤液到入5倍量水中,用二氯甲烷萃取,萃取液分别用饱和碳酸氢钠溶液及蒸馏水洗至中性,无水硫酸钠干燥,减压浓缩,硅胶柱层析,得浅黄色粘稠液体(III)。(4) Take 2 g of compound (VIII) and add 40 g of glacial acetic acid to dissolve it, add 6 g of zinc powder, stir and reflux for 20 to 24 hours. Suction filtration while hot, pour the filtrate into 5 times the amount of water, extract with dichloromethane, wash the extract with saturated sodium bicarbonate solution and distilled water to neutrality, dry over anhydrous sodium sulfate, concentrate under reduced pressure, and perform silica gel column chromatography. A light yellow viscous liquid (III) was obtained.

(5)取化合物(VIII)加入二氯甲烷溶解(浓度约为2.5~10%),加入结晶硫酸铜及高锰酸钾混合物粉末,再加入适量叔丁醇及水,室温下搅拌2小时。减压除去二氯甲烷,渣块用乙酸乙酯溶解,然后加10%亚硫酸钠溶液洗涤至无色,水洗至中性,无水硫酸钠干燥,减压浓缩,得白色固体(IXa)。将其加入丙酮溶解,加入适量高氯酸,室温下搅拌24小时,用饱和碳酸氢钠溶液调pH至中性,减压蒸去丙酮,用二氯甲烷萃取,无水硫酸钠干燥,减压浓缩,得白色固体(X)。(5) Dissolve compound (VIII) in dichloromethane (concentration is about 2.5-10%), add crystalline copper sulfate and potassium permanganate mixture powder, add appropriate amount of tert-butanol and water, and stir at room temperature for 2 hours. The dichloromethane was removed under reduced pressure, and the residue was dissolved in ethyl acetate, then washed with 10% sodium sulfite solution until it was colorless, washed with water until neutral, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a white solid (IXa). Dissolve it in acetone, add an appropriate amount of perchloric acid, stir at room temperature for 24 hours, adjust the pH to neutral with saturated sodium bicarbonate solution, evaporate the acetone under reduced pressure, extract with dichloromethane, dry over anhydrous sodium sulfate, and depressurize Concentration gave white solid (X).

(6)将上步产物(X)1g加到500mL3%的氢氧化钾甲醇溶液,加热回流30分钟,用5%盐酸调整溶液的pH为中性,减压蒸馏除去甲醇,乙酸乙酯萃取三次,有机层合并用无水硫酸钠干燥,减压蒸去溶剂,得浅黄色固体,硅胶柱层析,得白色固体(I)。(6) Add 1 g of the product (X) from the previous step to 500 mL of 3% potassium hydroxide methanol solution, heat to reflux for 30 minutes, adjust the pH of the solution to neutral with 5% hydrochloric acid, remove methanol by distillation under reduced pressure, and extract three times with ethyl acetate , the organic layers were combined and dried with anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a light yellow solid, which was subjected to silica gel column chromatography to obtain a white solid (I).

实施例2Example 2

胆甾-3β,5α,6β,19-四羟基-24-酮的合成Synthesis of Cholesta-3β, 5α, 6β, 19-tetrahydroxy-24-one

(1)~(4)与实施例1的步骤(1)~(4)相同。(1)-(4) are the same as steps (1)-(4) of Example 1.

(5)取化合物(VIII)加入二氯甲烷溶解(浓度约为2.5~10%),加入间氯过氧苯甲酸,室温下搅拌2小时。减压除去二氯甲烷,渣块用乙酸乙酯溶解,然后加10%亚硫酸钠溶液洗涤至无色,水洗至中性,无水硫酸钠干燥,减压浓缩,得白色固体(IXa)。将其加入丙酮溶解,加入适量高氯酸,室温下搅拌24小时,用饱和碳酸氢钠溶液调pH至中性,减压蒸去丙酮,用二氯甲烷萃取,无水硫酸钠干燥,减压浓缩,得白色固体(X)。(5) Take compound (VIII) and add dichloromethane to dissolve (concentration is about 2.5-10%), add m-chloroperoxybenzoic acid, and stir at room temperature for 2 hours. The dichloromethane was removed under reduced pressure, and the residue was dissolved in ethyl acetate, then washed with 10% sodium sulfite solution until it was colorless, washed with water until neutral, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a white solid (IXa). Dissolve it in acetone, add an appropriate amount of perchloric acid, stir at room temperature for 24 hours, adjust the pH to neutral with saturated sodium bicarbonate solution, evaporate the acetone under reduced pressure, extract with dichloromethane, dry over anhydrous sodium sulfate, and depressurize Concentration gave white solid (X).

(6)与实施1的步骤(6)相同。(6) is the same as step (6) of Implementation 1.

实施例3Example 3

胆甾-3β,5α,6β,19-四羟基-24-酮的合成Synthesis of Cholesta-3β, 5α, 6β, 19-tetrahydroxy-24-one

(1)~(4)与实施例1的步骤(1)~(4)相同。(1)-(4) are the same as steps (1)-(4) of Example 1.

(5)取化合物(VIII)加入88%甲酸溶解(浓度约为5%),沸水浴加热5分钟,冷却至室温,加入30%过氧化氢溶液,室温放置24小时,用水稀释后,用乙酸乙酯萃取,然后加10%亚硫酸钠溶液洗涤至无色,水洗至中性,无水硫酸钠干燥,减压浓缩,得白色固体(IXb)。(5) Take compound (VIII) and add 88% formic acid to dissolve (concentration is about 5%), heat in a boiling water bath for 5 minutes, cool to room temperature, add 30% hydrogen peroxide solution, leave it at room temperature for 24 hours, dilute with water, and wash with acetic acid Extract with ethyl ester, then add 10% sodium sulfite solution to wash until colorless, wash with water until neutral, dry over anhydrous sodium sulfate, and concentrate under reduced pressure to obtain a white solid (IXb).

(6)将上步产物(IXb)1g加到500L3%的氢氧化钾甲醇溶液,加热回流30分钟,用5%盐酸调整溶液的pH为中性,减压蒸馏除去甲醇,乙酸乙酯萃取三次,有机层合并用无水硫酸钠干燥,减压蒸去溶剂,得浅黄色固体,硅胶柱层析,得白色固体(I)。(6) Add 1 g of the previous step product (IXb) to 500 L of 3% potassium hydroxide methanol solution, heat to reflux for 30 minutes, adjust the pH of the solution to be neutral with 5% hydrochloric acid, remove methanol by distillation under reduced pressure, and extract three times with ethyl acetate , the organic layers were combined and dried with anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a light yellow solid, which was subjected to silica gel column chromatography to obtain a white solid (I).

实施例4Example 4

24-亚甲基-胆甾-3β,5α,6β,19-四醇的合成Synthesis of 24-methylene-cholesta-3β, 5α, 6β, 19-tetrol

(1)~(6)与实施例1的步骤(1)~(6)相同。(1)-(6) are the same as steps (1)-(6) of Example 1.

(7)在50mL无水四氢呋喃溶液中加入2克甲基三苯基溴化膦,通氮气,注入适量的正丁基锂,室温下搅拌反应6小时,将1克(I)的四氢呋喃溶液注入反应体系,继续反应2小时,将反应液迅速倒入饱和的氯化铵溶液中,用乙醚萃取,醚层用无水硫酸钠干燥,减压蒸去溶剂,得浅黄色固体,硅胶柱层析,得白色固体(II)。(7) Add 2 grams of methyltriphenylphosphine bromide to 50 mL of anhydrous tetrahydrofuran solution, ventilate nitrogen, inject an appropriate amount of n-butyllithium, stir and react at room temperature for 6 hours, inject 1 gram of tetrahydrofuran solution of (I) The reaction system was continued to react for 2 hours, the reaction solution was quickly poured into a saturated ammonium chloride solution, extracted with ether, the ether layer was dried with anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a light yellow solid, which was subjected to silica gel column chromatography. , to give white solid (II).

实施例5Example 5

胆甾-3β,5α,6β,19-四羟基-24-双腙的合成Synthesis of Cholesta-3β, 5α, 6β, 19-tetrahydroxy-24-dihydrazone

(1)~(6)与实施例1的步骤(1)~(6)相同。(1)-(6) are the same as steps (1)-(6) of Example 1.

(7)将1克(I)用10mL乙醇溶解,加入1mL50%肼的水溶液,加热回流4小时,减压蒸去溶剂,加入适量水,调pH为中性,乙酸乙酯萃取,得白色固体,硅胶柱层析,得白色固体(III)。(7) Dissolve 1 gram of (I) in 10 mL of ethanol, add 1 mL of 50% hydrazine aqueous solution, heat to reflux for 4 hours, evaporate the solvent under reduced pressure, add an appropriate amount of water, adjust the pH to neutral, extract with ethyl acetate to obtain a white solid , silica gel column chromatography to give white solid (III).

实施例6Example 6

胆甾-3β,5α,6β,19-四羟基-24-双腙的合成Synthesis of Cholesta-3β, 5α, 6β, 19-tetrahydroxy-24-dihydrazone

(1)~(6)与实施例1的步骤(1)~(6)相同。(1)-(6) are the same as steps (1)-(6) of Example 1.

(7)将1克(I)用20mL乙醇溶解,加入1mL80%肼的水溶液,加热回流2小时,减压蒸去溶剂,加入适量水,调pH为中性,乙酸乙酯萃取,得白色固体,硅胶柱层析,得白色固体(III)。(7) Dissolve 1 gram of (I) in 20 mL of ethanol, add 1 mL of 80% hydrazine aqueous solution, heat to reflux for 2 hours, evaporate the solvent under reduced pressure, add an appropriate amount of water, adjust the pH to neutral, extract with ethyl acetate to obtain a white solid , silica gel column chromatography to give white solid (III).

目的产物1:胆甾-3β,5α,6β,19-四羟基-24-酮的结构确证Target product 1: Confirmation of the structure of cholestan-3β, 5α, 6β, 19-tetrahydroxy-24-one

熔点:213-214℃Melting point: 213-214°C

元素分析:C27H46O5测定值:C,71.60;H,20.50;理论值:C,71.92;H,10.29,Elemental analysis: C 27 H 46 O 5 Found: C, 71.60; H, 20.50; Theoretical: C, 71.92; H, 10.29,

MS:[M+Na]+=473MS: [M+Na] + = 473

IR:3324,2941,2889,1708,1464,1380,1342,1048,975.IR: 3324, 2941, 2889, 1708, 1464, 1380, 1342, 1048, 975.

1HNMR(DMSO): 1HNMR (DMSO):

3.99(1H,d,19-CH),3.86(m,1H,3β-CH),3.52(1H,m,19-CH),3.23(m,1H,6β-CH),2.59(1H,m,25-CH),1.18(3H,d,26-CH3,27-CH3),1.01(3H,s,19-CH3),0.87(3H,d,21-CH3),0.65(3H,s,18-CH3).3.99 (1H, d, 19-CH), 3.86 (m, 1H, 3β-CH), 3.52 (1H, m, 19-CH), 3.23 (m, 1H, 6β-CH), 2.59 (1H, m, 25-CH), 1.18 (3H, d, 26-CH 3 , 27-CH 3 ), 1.01 (3H, s, 19-CH 3 ), 0.87 (3H, d, 21-CH 3 ), 0.65 (3H, s, 18-CH 3 ).

13CNMR(DMSO): 13 CNMR (DMSO):

214.2(C),74.5(C),73.8(CH),65.8(CH),62.0(CH2),56.5(CH),55.5(CH),44.9(CH),42.53(C),42.47(CH),41.0(C),40.3(CH2),39.8(CH),36.4(CH),34.9(CH2),33.9(CH2),31.1(CH2),30.8(CH2),29.3(CH2),27.7(CH2),26.8(CH2),23.8(CH2),21.7(CH3),18.3(CH3),18.1(CH3),18.0(CH3),13.1(CH3).214.2(C), 74.5(C), 73.8(CH), 65.8(CH), 62.0( CH2 ), 56.5(CH), 55.5(CH), 44.9(CH), 42.53(C), 42.47(CH) , 41.0(C), 40.3(CH 2 ), 39.8(CH), 36.4(CH), 34.9(CH 2 ), 33.9(CH 2 ), 31.1(CH 2 ), 30.8(CH 2 ), 29.3(CH 2 ), 27.7(CH 2 ), 26.8(CH 2 ), 23.8(CH 2 ), 21.7(CH 3 ), 18.3(CH 3 ), 18.1(CH 3 ), 18.0(CH 3 ), 13.1(CH 3 ).

目的产物2:24-亚甲基-胆甾-3β,5α,6β,19-四醇的结构确证Target product 2: Confirmation of the structure of 24-methylene-cholesta-3β, 5α, 6β, 19-tetrol

熔点:223-225℃Melting point: 223-225°C

元素分析:C28H48O4测定值:C,75.20;H,10.36理论值:C,74.95;H,10.78,Elemental analysis: C 28 H 48 O 4 Found: C, 75.20; H, 10.36 Theoretical: C, 74.95; H, 10.78,

MS:[M-H2O]+=432,MS: [MH 2 O] + = 432,

IR:3416,3028,2936,2868,1642,1464,1377,1057IR: 3416, 3028, 2936, 2868, 1642, 1464, 1377, 1057

1HNMR(DMSO): 1HNMR (DMSO):

5.25(1H,d,6β-OH),4.71(1H,d,J=1.5Hz,28-CH),4.65(1H,d,J=1.5Hz,28-CH),4.51(1H,d,19-OH),4.16(1H,d,3-CH),4.01(1H,d,19-CH),3.84(1H,m,3-CH),3.64(1H,s,5-OH),3.23(1H,m,6-CH),2.25(1H,m,25-CH),1.13(6H,d,26-CH3,27-CH3),1.01(3H,s,19-CH3),0.87(3H,d,21-CH3),0.67(3H,s,18-CH3).5.25 (1H, d, 6β-OH), 4.71 (1H, d, J = 1.5Hz, 28-CH), 4.65 (1H, d, J = 1.5Hz, 28-CH), 4.51 (1H, d, 19 -OH), 4.16 (1H, d, 3-CH), 4.01 (1H, d, 19-CH), 3.84 (1H, m, 3-CH), 3.64 (1H, s, 5-OH), 3.23 ( 1H, m, 6-CH), 2.25 (1H, m, 25-CH), 1.13 (6H, d, 26-CH 3 , 27-CH 3 ), 1.01 (3H, s, 19-CH 3 ), 0.87 (3H, d, 21-CH 3 ), 0.67 (3H, s, 18-CH 3 ).

13CNMR(DMSO): 13 CNMR (DMSO):

156.6(C),107.3(CH2),75.4(C),74.7(CH),66.7(CH),63.0(CH2),57.4(CH),56.7(CH),45.9(CH),43.5(C),43.3(CH),42.8(C),41.3(CH2),40.9(CH),37.4(CH2),36.1(CH),33.9(CH2),31.8(CH2),31.4(CH2),30.5(CH2),28.7(CH2),27.9(CH2),24.70(CH2),22.64(CH3),22.57(CH3),19.4(CH3),13.1(CH3).156.6(C), 107.3( CH2 ), 75.4(C), 74.7(CH), 66.7(CH), 63.0( CH2 ), 57.4(CH), 56.7(CH), 45.9(CH), 43.5(C ), 43.3(CH), 42.8(C), 41.3(CH 2 ), 40.9(CH), 37.4(CH 2 ), 36.1(CH), 33.9(CH 2 ), 31.8(CH 2 ), 31.4(CH 2 ), 30.5(CH 2 ), 28.7(CH 2 ), 27.9(CH 2 ), 24.70(CH 2 ), 22.64(CH 3 ), 22.57(CH 3 ), 19.4(CH 3 ), 13.1(CH 3 ).

目的产物3:胆甾-3β,5α,6β,19-四羟基-24-双腙的结构确证Target product 3: Confirmation of the structure of cholestan-3β, 5α, 6β, 19-tetrahydroxy-24-dihydrazone

熔点:270-272℃Melting point: 270-272°C

元素分析:C54H92O4N2测定值:C,70.92;H,10.44;N,2.98 理论值:C,72.27;H,10.33;N,3.12Elemental analysis: Found for C 54 H 92 O 4 N 2 : C, 70.92; H, 10.44; N, 2.98 Theoretical: C, 72.27; H, 10.33; N, 3.12

MS:[M+1]+=897MS: [M+1] + = 897

IR:3318,2943,2870,1628,1464,1379,1344,1060,976。IR: 3318, 2943, 2870, 1628, 1464, 1379, 1344, 1060, 976.

1HNMR(DMSO): 1HNMR (DMSO):

5.38(1H,t,6β-H),4.71(1H,d,J=1.5Hz,28-CH),4.65(1H,d,J=1.5Hz,28-CH),3.52(1H,m,3-CH),2.28(1H,m,25-CH),1.13(6H,d,26-CH3,27-CH3),1.01(3H,s,19-CH3),0.91(3H,d,21-CH3),0.69(3H,s,18-CH3).5.38 (1H, t, 6β-H), 4.71 (1H, d, J=1.5Hz, 28-CH), 4.65 (1H, d, J=1.5Hz, 28-CH), 3.52 (1H, m, 3 -CH), 2.28 (1H, m, 25-CH), 1.13 (6H, d, 26-CH 3 , 27-CH 3 ), 1.01 (3H, s, 19-CH 3 ), 0.91 (3H, d, 21-CH 3 ), 0.69 (3H, s, 18-CH 3 ).

13CNMR(DMSO): 13 CNMR (DMSO):

169.3(C),75.4(C),74.7(CH),66.8(CH),63.6(CH2),57.5(CH),56.4(CH),45.9(CH),43.5(C),42.8(C),41.3(CH2),40.8(CH),37.4(CH2),35.8(CH),35.6(CH2),33.9(CH2),31.8(CH2),31.4(CH2),30.5(CH2),28.7(CH2),27.9(CH2),24.70(CH2),22.5(CH3),21.4(CH3),19.2(CH3),18.9(CH3),13.1(CH3).169.3(C), 75.4(C), 74.7(CH), 66.8(CH), 63.6( CH2 ), 57.5(CH), 56.4(CH), 45.9(CH), 43.5(C), 42.8(C) , 41.3(CH 2 ), 40.8(CH), 37.4(CH 2 ), 35.8(CH), 35.6(CH 2 ), 33.9(CH 2 ), 31.8(CH 2 ), 31.4(CH 2 ), 30.5(CH 2 ), 28.7 (CH 2 ), 27.9 (CH 2 ), 24.70 (CH 2 ), 22.5 (CH 3 ), 21.4 (CH 3 ), 19.2 (CH 3 ), 18.9 (CH 3 ), 13.1 (CH 3 ) .

Claims (8)

1. courage steroid-3 β, 5 α, 6 β, the synthetic method of 19-tetrahydroxy-24-ketone and derivative, it is characterized in that with the Hyodeoxycholic Acid being raw material, prepare 3 β-acetoxyl group-courage steroid-5-alkene-24-acid, by become courage steroid acyl chlorides with the sulfur oxychloride prepared in reaction, the ultrasonic wave radiation down and the sec.-propyl cadion react 3 β-acetoxyl group-courage steroid-5-alkene-24-ketone, obtain 3 β-acetoxyl group-courage steroid-5 α-bromo-6 beta-hydroxies-24-ketone with N-bromo-succinimide/high chloro acid solution's system reaction again, generate 3 β-acetoxyl group-courage steroid-5 α-bromo-6 β with the diacetoxy phenyl-iodide afterwards, 19-epoxy-24-ketone, generate 3 β with zinc powder/Glacial acetic acid reduction system, 19-diacetoxy-courage steroid-5-alkene-24-ketone; Use 5,6 two keys of oxygenant oxidation again, hydrolysis reaction gets courage steroid-3 β, 5 α, 6 β, 19-tetrahydroxy-24-ketone; Last and methyltriphenylphosphonium bromide reacts Synthetic 2 4-methylene radical-courage steroid-3 β, 5 α, 6 β, 19-tetrol; With synthetic courage steroid-3 β of hydrazine reaction, 5 α, 6 β, the two hydrazones of 19-tetrahydroxy-24-.
2. synthetic method according to claim 1 is characterized in that concrete reactions steps is:
(1) IV is dissolved in dry-out benzene and adds sulfur oxychloride, add the pyridine of catalytic amount, at room temperature stirred 2~4 hours, be evaporated to driedly, add benzene again and continue to concentrate, take residual sulfur oxychloride out of, yellow heavy-gravity liquid;
(2) take by weighing dry magnesium powder, add anhydrous diethyl ether, drip different N-PROPYLE BROMIDE/anhydrous ether solution, add back ultrasonic radiation 15~30 minutes, add Cadmium chloride fine powder after the cooling in batches, stirring under the ultrasonic wave radiation under 25~40 ℃, the ice bath cooling down, slowly be added drop-wise to 30~40% dry-out benzene solution of product of last step in the reaction system, drip off the back and continue ultrasonic wave radiation backflow 1~2 hour, after the ice bath cooling, drip 1: 1 aqueous hydrochloric acid, extract with benzene, the benzene layer is washed till neutrality with distilled water, drying, concentrating under reduced pressure, silica gel column chromatography gets white solid V;
(3) extracting waste solid V adds organic solvent dissolution, adds HClO again 4And water, under the lucifuge condition, adding the N-succimide then in batches, controlled temperature is lower than 10 ℃, reacts 1~2 hour down at 15~20 ℃ afterwards, adds 10%Na in reaction solution 2S 2O 8The aqueous solution, after the layering, the upper strata concentrates, the CH of lower floor 2Cl 2Extraction merges organic layer, uses saturated NaHCO 3Solution washing is washed with distilled water to neutrality again, drying, and concentrating under reduced pressure, silica gel column chromatography gets white solid VI;
(4) get compound VI, dissolve in hexanaphthene/benzene mixed solution, add oxygenant, under 20~40 ℃ of stirrings, ultra violet lamp 7~8 hours, reaction solution is used 10% sodium thiosulfate solution successively, saturated NaHCO 3Solution and distilled water wash are extremely neutral, drying, and concentrating under reduced pressure gets light yellow compound VI I;
(5) get compound VIII and add the Glacial acetic acid dissolving, add zinc powder, stirring and refluxing 20~24 hours; Suction filtration while hot, filtrate is used dichloromethane extraction, extraction liquid is washed till neutrality with saturated sodium bicarbonate solution and distilled water respectively, drying, concentrating under reduced pressure, silica gel column chromatography, light yellow thick liquid VIII;
(6) get compound VIII and add the methylene dichloride dissolving, add oxygenant, stir under the room temperature, methylene dichloride is removed in decompression, the clinker acetic acid ethyl dissolution adds the washing of 10% sodium sulfite solution then to colourless, is washed to neutrality, drying, concentrating under reduced pressure gets white solid IXa, it is added acetone solution, add perchloric acid, stir under the room temperature, transfer pH to neutral, pressure reducing and steaming acetone is used dichloromethane extraction, drying, concentrating under reduced pressure gets white solid X;
(7) get compound VIII and add the dissolving of 88% formic acid, boiling water bath heating 5 minutes is cooled to room temperature, adds oxygenant, room temperature was placed 24 hours, behind the dilute with water, use ethyl acetate extraction, add the washing of 10% sodium sulfite solution then to colourless, be washed to neutrality, drying, concentrating under reduced pressure gets white solid IXb;
(8) will go up step product IXb or X is dissolved in the methyl alcohol, adding concentration is 3% potassium hydroxide alcoholic solution, reflux 15~30 minutes, it is neutral transferring pH, methyl alcohol is removed in underpressure distillation, ethyl acetate extraction, the organic layer drying, the pressure reducing and steaming solvent gets light yellow solid, silica gel column chromatography gets white solid I;
(9) methyltriphenylphosphonium bromide is added in the anhydrous tetrahydrofuran solution, inject n-Butyl Lithium, injection rate just is dissolved as suitable with methyltriphenylphosphonium bromide, stirring reaction is 4~6 hours under the room temperature, I in the last step is added reaction system, continue reaction 2~3 hours, reaction solution is poured into rapidly in the saturated ammonium chloride solution, use extracted with diethyl ether, ether layer drying, the pressure reducing and steaming solvent gets light yellow solid, silica gel column chromatography gets white solid II;
(10) I is added dissolve with ethanol, add in the aqueous solution of hydrazine, separate thermal backflow, the pressure reducing and steaming solvent adds entry, and it is neutral transferring pH, and ethyl acetate extraction gets white solid, and silica gel column chromatography gets white solid III;
In the above-mentioned steps, I represents courage steroid-3 β, 5 α, 6 β, 19-tetrahydroxy-24-ketone; II represents 24-methylene radical-courage steroid-3 β, 5 α, 6 β, 19-tetrol; III represents courage steroid-3 β, 5 α, 6 β, the two hydrazones of 19-tetrahydroxy-24-; IV represents 3 β-acetoxyl group-courage steroid-5-alkene-24-acid; V represents 3 β-acetoxyl group-courage steroid-5-alkene-24-ketone; VI represents 3 β-acetoxyl group-courage steroid-5 α-bromo-6 beta-hydroxies-24-ketone; VII represents 3 β-acetoxyl group-courage steroid-5 α-bromo-6 β, 19-epoxy-24-ketone; VIII represents 3 β, 19-diacetoxy-courage steroid-5-alkene-24-ketone; IXa represents 3 β, 19-diacetoxy-courage steroid-5,6 beta epoxides-24-ketone; IXb represents 3 β, 19-diacetoxy-courage steroid-5,6 α-epoxy-24-ketone; X represents 3 β, 19-diacetoxy-courage steroid-5,6-dihydroxyl-24-ketone.
3. synthetic method according to claim 2 is characterized in that the concentration of the benzole soln of II in the step (1) is 25~45%, and the amount of sulfur oxychloride is 1.0~2.0 times of mole number of II.
4. synthetic method according to claim 2, the amount of magnesium powder in the step (2) of it is characterized in that are 1.2~3.0 times of mole number of II.
5. synthetic method according to claim 2 is characterized in that the organic solvent in the step (3) is tetrahydrofuran (THF) or dioxane.
6. synthetic method according to claim 2 is characterized in that the oxygenant in the step (4) is diacetoxy phenyl-iodide or lead tetra-acetate.
7. synthetic method according to claim 2 is characterized in that the oxygenant in the step (6) is potassium permanganate/copper sulfate or metachloroperbenzoic acid.
8. synthetic method according to claim 2 is characterized in that the oxygenant in the step (7) is 30% hydrogen peroxide.
CNB200510121374XA 2005-12-31 2005-12-31 Synthetic method of cholestan-3β, 5α, 6β, 19-tetrahydroxy-24-one and derivatives thereof Expired - Lifetime CN100436474C (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CNB200510121374XA CN100436474C (en) 2005-12-31 2005-12-31 Synthetic method of cholestan-3β, 5α, 6β, 19-tetrahydroxy-24-one and derivatives thereof
AU2006332419A AU2006332419A1 (en) 2005-12-31 2006-07-10 The use of phthalide derivatives
PCT/CN2006/001627 WO2007076655A1 (en) 2005-12-31 2006-07-10 METHOD FOR SYNTHESIS OF CHOLEST-3β,5α,6β,19-TETRAHYDROXY-24-ONE AND ITS DERIVATIVES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB200510121374XA CN100436474C (en) 2005-12-31 2005-12-31 Synthetic method of cholestan-3β, 5α, 6β, 19-tetrahydroxy-24-one and derivatives thereof

Publications (2)

Publication Number Publication Date
CN1793159A true CN1793159A (en) 2006-06-28
CN100436474C CN100436474C (en) 2008-11-26

Family

ID=36804818

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200510121374XA Expired - Lifetime CN100436474C (en) 2005-12-31 2005-12-31 Synthetic method of cholestan-3β, 5α, 6β, 19-tetrahydroxy-24-one and derivatives thereof

Country Status (2)

Country Link
CN (1) CN100436474C (en)
WO (1) WO2007076655A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104497086A (en) * 2014-12-12 2015-04-08 中山大学 Androstane-3beta, 5alpha, 6beta,19-tetraol as well as preparation method and application thereof
WO2016165496A1 (en) * 2015-04-14 2016-10-20 诺瑞特国际药业股份有限公司 Method for preparing deoxycholic acid

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114671796B (en) * 2022-04-22 2024-06-11 宁波工程学院 Method for synthesizing N-alkyl phthalimide by photocatalysis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5573700A (en) * 1978-11-30 1980-06-03 Teijin Ltd Preparation of steroidal ketone compound
WO1994020520A1 (en) * 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
CN1448399A (en) * 2003-04-24 2003-10-15 中山大学 Synthetic method of 24-methylene-cholesterol-5-alkenyl-3 beta, 19-glycol
CN1448400A (en) * 2003-05-06 2003-10-15 中山大学 Synthetic method of 24-methylene-cholesterol-3 beta, 5 alpha, 6 beta,19-tetraalcohol
CN1583782A (en) * 2004-05-28 2005-02-23 中山大学 Synthesis of 24-submethyl-cholesterol-5-ene-3 beta, 7 beta, 19-trialcohol
CN1583781A (en) * 2004-05-28 2005-02-23 中山大学 Synthesis of 3 beta, 7 beta, 19-tricarboxy-5-ene-cholestane

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104497086A (en) * 2014-12-12 2015-04-08 中山大学 Androstane-3beta, 5alpha, 6beta,19-tetraol as well as preparation method and application thereof
WO2016165496A1 (en) * 2015-04-14 2016-10-20 诺瑞特国际药业股份有限公司 Method for preparing deoxycholic acid

Also Published As

Publication number Publication date
CN100436474C (en) 2008-11-26
WO2007076655A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
JP7224307B2 (en) Methods and intermediates for the preparation of bile acid derivatives
US4183852A (en) Process for preparing 25-hydroxycholesterol
CN101065396A (en) Process for the preparation of drospirenone
CN100343269C (en) Synthesis of estetrol via estrone-derived steroids
CN103965277B (en) A kind of method from sterol fermented product synthesis difluprednate
CN102060902A (en) Chenodeoxycholic acid synthesis method
CN1793159A (en) Process for synthesizing cholester-3 bata, 5 alpha, 6 bata, 19-tetrahydroxy-24-one and derivative
CN1099758A (en) New preparation process for 6alpha, 9alpha-difluorinated steroids and new intermediates
CN1120844C (en) Lactone compound and its synthesis and use
US20130211069A1 (en) Process for the preparation of 17-desoxy-corticosteroids
CN1061985C (en) Method for preparation of progestol by degradation of steroidal saponin
JP4438308B2 (en) Method for producing steroid compound
JP3037508B2 (en) Novel substituted 16-methyl steroid derivatives of pregna-1,4-diene-3,20-dione, their preparation, their use in the preparation of 16-methylene steroids and novel intermediates
CN1031576C (en) Steroid products containing, in position 23 sulphinyl radical, process for preparing them, their use for preparing products 20-ketopregnane series
Durán et al. Synthesis of 6-thia analogs of the natural neurosteroid allopregnanolone
CN100410270C (en) Synthetic method of cholest-5-ene-3β, 19-dihydroxy-24-one and its derivatives
CN115611962A (en) Method for synthesizing cholic acid
CN1209138A (en) Preparation method of 9,11β-epoxy steroid compound
CN101676296B (en) Method for preparing 21-position carboxylate steroid compound and steroid compound prepared by the method
Ibrahim-Ouali et al. First synthesis of thia steroids from cholic acid
CN1308085A (en) Preparation process of deoxycholeic acid of bear
CN1448400A (en) Synthetic method of 24-methylene-cholesterol-3 beta, 5 alpha, 6 beta,19-tetraalcohol
CN1793160A (en) Process for synthesizing cholester-5-ylene-3bata-hydroxy-24-one and derivative
CN1800198A (en) Method for preparing macrolides half-synthesized antibiotics telithromycin
CN100345864C (en) Preparation method of steroid medicine for treating respiration channel disease and its intermediate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: GUANGZHOU SEPATEC PHARMACEUTICAL TECHNOLOGY CO., L

Free format text: FORMER OWNER: ZHONGSHAN UNIVERSITY

Effective date: 20120704

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 510275 NO.135, XINGANG ROAD(WEST), GUANGZHOU CITY, GUANGDONG PROVINCE TO: 510663 C208, GUOJIQIYEFUHUAQI, GUANG STATE, NO.3, JUQUAN ROAD, GUANGZHOU CITY SCIENCE CITY, GUANGDONG PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20120704

Address after: 510663 Guangdong province Guangzhou Science City skim Springs Road No. 3, Guangzhou international business incubator C208

Patentee after: GUANGZHOU CELLPROTEK PHARMACEUTICAL Co.,Ltd.

Address before: 510275 Xingang West Road, Guangdong, China, No. 135, No.

Patentee before: Sun Yat-sen University

C56 Change in the name or address of the patentee
CP03 Change of name, title or address

Address after: Moon Road, Science City high tech Industrial Development Zone of Guangzhou City, Guangdong province 510663 No. 3 Guangzhou international business incubator C District No. G401-415 room

Patentee after: GUANGZHOU CELLPROTEK PHARMACEUTICAL Co.,Ltd.

Address before: 510663 Guangdong province Guangzhou Science City skim Springs Road No. 3, Guangzhou international business incubator C208

Patentee before: GUANGZHOU CELLPROTEK PHARMACEUTICAL Co.,Ltd.

CX01 Expiry of patent term

Granted publication date: 20081126

CX01 Expiry of patent term